Cucurbitacin-B inhibits neuroblastoma cell proliferation through up-regulation of PTEN

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 21, 2014, Pages 3297-3303

  Shang, Y ^a   Guo, X X ^a   Li, W W ^a   Rao, W ^a   Chen, M L ^a   Mu, L N ^a   Li, S J ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis (AS); Homocysteine (Hcy); Lutein; Oxidative stress

Indexed keywords

ANTIMITOTIC AGENT; BROXURIDINE; CUCURBITACIN; CUCURBITACIN B; CYCLIN D1; CYCLIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PTEN PROTEIN, HUMAN; TRITERPENE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; IN VITRO STUDY; MTT ASSAY; NEUROBLASTOMA CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; APOPTOSIS; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; NEUROBLASTOMA; OXIDATIVE STRESS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; NEUROBLASTOMA; OXIDATIVE STRESS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRITERPENES; UP-REGULATION;

EID: 84936999180     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. TONINI G P, NAKAGAWARA A, BERTHOLD F. Towards a turning point of neuroblastoma therapy. Cancer Lett 2012;326:128-134.
2. PIETRAS W. Advances and changes in the treatment of children with nephroblastoma. Adv Clin Exp Med 2012;21:809-820.
3. GAINS J, MANDEVILLE H, CORK N, BROCK P, GAZE M. Ten challenges in the management of neuroblas-toma. Future Oncol 2012;8:839-858.
4. MALONEY KN, FUJITA M, EGGERT US, SCHROEDER FC, FIELD CM, MITCHISON TJ, CLARDY J. Actin-aggregat-ing cucurbitacins from Physocarpus capitatus. J Nat Prod 2008;71:1927-1929.
5. ALGHASHAM AA. Cucurbitacins-a promising target for cancer therapy. Int J Health Sci (Qassim) 2013;7:77-89.
6. HENRICH CJ, THOMAS CL, BROOKS AD, BOOTH NL, LOWERY EM, POMPEI RJ, MCMAHON JB, SAYERS T. Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis. Apoptosis 2012;17:79-89.
7. ISHII T, KIRA N, YOSHIDA T, NARAHARA H. Cucurbitacin D induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial and ovarian cancer cells. Tumor Biol 2013;34:285-291.
8. ZHANG T, LI J, DONG Y, ZHAI D, LAI L, DAI F, DENG H, CHEN Y, LIU M, YI Z. Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Treat 2012;135:445-458.
9. KAUSAR H, MUNAGALA R, BANSAL SS, AQIL F, VADHANAM MV, GUPTA RC. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. Cancer Lett 2013;332:35-45.
10. LU P, YU B, XU J. Cucurbitacin B regulates immature myeloid cell differentiation and enhances an-titumor immunity in patients with lung cancer. Cancer Biother Radiopharm 2012;27:495-503.
11. HARDIE DG. The LKB1-AMPK pathway-friend or foe in cancer? Cancer Cell 2013;23:131-132.
12. KUO H P, CHUANG TC, TSAI SC, TSENG HH, MSU SC, CHEN YC, KUO CL, KUO YH, LIU JY, KAO MC. Berber-ine, an isoquinoline alkaloid, inhibits the metastat-ic potential of breast cancer cells via Akt pathway modulation. J Agric Food Chem 2012;60:9649-9658.
13. JIN F, IRSHAD S, YU W, BELAKAVADI M, CHEKMAREVA M, ITTMANN MM, ABATE-SHEN C, FONDELL BD. ERK and AKT Signaling Drive MED1 Overexpression in prostate cancer in association with elevated proliferation and tumorigenicity. Mol Cancer Res 2013;11:736-747.
14. MICHELS S, TRAUTMANN M, SIEVERS E, KINDLER D, HUSS S, RENNER M, FRIEDRICHS N, KIRFEL J, STEINER S, ENDL E, WURST P, HEUKAMP L, PENZEL R, LARSSON O, KAWAI A, TANAKA S, SONOBE H, SCHIRMACHER P, MECHTERSHEIMER G, WARDELMANN E, BÜTTNER R, HARTMANN W. SRC signaling is crucial in the growth of synovial sarcoma cells. Cancer Res 2013;73:2518-2528.
15. WANG ZH, SHANG YY, ZHANG S, ZHONG M, WANG X P, DENG JT, PAN J, ZHANG Y, ZHANG W. Silence of TRIB3 suppresses atherosclerosis and stabilizes plaques in diabetic ApoE-/-/LDL receptor-/-mice. Diabetes 2012;61:463-473.
16. WIART C. The definition and significance of Cucur-bitacin B a STAT3 inhibitors. Cancer Lett 2013;328:188.
17. VANHAESEBROECK B, STEPHENS L, HAWKINS P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012;13:195-203.
18. HOLLANDER MC, BLUMENTHAL GM, DENNIS PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models Nat Rev Cancer 2011;11:289-301.
19. BUNNEY TD, KATAN M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010;10:342-352.
20. HOEBEECK J, MICHELS E, PATTYN F, COMBABET V, VERMEULEN J, YIGIT N, HOYOUX C, LAUREYS G, DE PAEPE A, SPELEMAN F, VANDESOMPELE J. Aberrant methylation of candidate tumor suppressor genes in neurob-lastoma. Cancer Lett 2009;273:336-346.
21. SARTELET H, OLIGNY LL, VASSAL G. AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther 2008;8:757-769.